Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Finance Watch: BIO Report Shows Record VC Funding Across Geographies

Executive Summary

Private Company Edition: Venture capital for emerging therapeutics companies in the US and in ex-US regions reached all-time highs in 2018. Also, Alphamab raises $60m Series B, three new VC funds launch and FLX changes its name to RAPT.

Advertisement

Related Content

Big Year For Israeli Tissue Agnostic Company Ayala
Finance Watch: Arteaus Comes Full Circle As Investors Monetize Emgality Royalties
Finance Watch: VC Deals Keep Up Fast Pace With $1.1bn In Less Than Three Weeks
Deal Watch: Cancer Remains Hot Target At J.P. Morgan
Finance Watch: Alphamab's $100m Series A Continues Theme Of Big Investments In China Biopharma
Finance Watch: Vaccinex, Aridis Launch August's First US IPOs As The Summer Simmer Slows
Finance Watch: Pfizer Ventures' Dalton Makes Sense Of Neuroscience Focus Within New $600m VC Fund Commitment
Israeli Startup Ayala Taking BMS Cancer Drug Into Phase II With $17m Financing
Inhibrx LLC
Tiny Inhibrx signs '$500 million' preclinical antibody outlicensing deal with Celgene

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC125325

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel